{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:08:32Z","timestamp":1791472112425,"version":"4.3.4"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The infliximab (IFX) biosimilar, CT-P13, is available as an intravenous (IV) and subcutaneous (SC) formulation. Although current indications allow the transition from IV CT-P13 to SC CT-P13 after two IV administrations, some clinicians prefer to postpone switching until stable clinical remission has been achieved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluate the endoscopic response, treatment persistence, clinical remission, endoscopic remission, and safety profile after one year of treatment with IFX in patients switched from IV to SC after 6 weeks (early switch group) or after 6 months (late switch group).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were no statistical differences between the two groups after one year in terms of endoscopic response (71.4% vs 70.8%, P = .95), steroid-free clinical remission (62.5% vs 68.7%, P\u2009=\u2009.51), or IFX retention rate (75.0% vs 66.7%, P\u2009=\u2009.35). We observed higher endoscopic remission rates in early switch patients as compared to late switch patients; however, this trend was not significant (69.6% vs 52.1%, P\u2009=\u2009.07). A return to IV-IFX was required in 1 of 43 early switch patients and in 3 of 44 late switch patients (2.3% vs 6.8%, P\u2009=\u2009.31). Clinical indexes, fecal calprotectin and C-reactive protein (CRP) levels significantly decreased after one year regardless of group. Adverse events were also comparable between groups (4.5% vs 8.3%, P\u2009=\u2009.46).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study has shown that early switch from IV-IFX to SC-IFX at 6 weeks is effective in terms of clinical and endoscopic remission at one year yielding similar results to late switch at 6 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf172","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T10:09:48Z","timestamp":1752746988000},"page":"3363-3369","source":"Crossref","is-referenced-by-count":8,"title":["When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8653-1790","authenticated-orcid":false,"given":"Lorenzo","family":"Bertani","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Tuscany North-West ASL, Pontedera Hospital , Pontedera,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Giuseppe","family":"Ribaldone","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Department of Medical Sciences, University of Turin , Turin,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Bossa","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology and Digestive Endoscopy, IRCCS Fondazione Casa Sollievo della Sofferenza , San Giovanni Rotondo,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Guerra","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology and Digestive Endoscopy, IRCCS Fondazione Casa Sollievo della Sofferenza , San Giovanni Rotondo,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Annese","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology and Digestive Endoscopy, IRCCS Fondazione Casa Sollievo della Sofferenza , San Giovanni Rotondo,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Manta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tuscany North-West ASL, Pontedera Hospital , Pontedera,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Armandi","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Department of Medical Sciences, University of Turin , Turin,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Caviglia","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Department of Medical Sciences, University of Turin , Turin,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-9496","authenticated-orcid":false,"given":"Alessia","family":"Todeschini","sequence":"additional","affiliation":[{"name":"IBD Unit, IRCCS Sacro Cuore Don Calabria Hospital , Negrar di Valpolicella,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Variola","sequence":"additional","affiliation":[{"name":"IBD Unit, IRCCS Sacro Cuore Don Calabria Hospital , Negrar di Valpolicella,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,7]]},"reference":[{"key":"2025120914514399700_izaf172-B1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2025120914514399700_izaf172-B2","doi-asserted-by":"publisher","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open."},{"key":"2025120914514399700_izaf172-B3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2025120914514399700_izaf172-B4","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3390\/nu13041387","article-title":"Inflammatory bowel diseases: is there a role for nutritional suggestions?","volume":"13","author":"Bertani","year":"2021","journal-title":"Nutrients."},{"key":"2025120914514399700_izaf172-B5","doi-asserted-by":"publisher","first-page":"7247238","DOI":"10.1155\/2019\/7247238","article-title":"A comprehensive review and update on the pathogenesis of inflammatory bowel disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J Immunol Res."},{"key":"2025120914514399700_izaf172-B6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/BTT.S207246","article-title":"Remicade((R)) (infliximab): 20 years of contributions to science and medicine","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biologics."},{"key":"2025120914514399700_izaf172-B7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med."},{"key":"2025120914514399700_izaf172-B8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/14712598.2018.1469620","article-title":"Progress with infliximab biosimilars for inflammatory bowel disease","volume":"18","author":"Kurti","year":"2018","journal-title":"Expert Opin Biol Ther."},{"key":"2025120914514399700_izaf172-B9","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/ecco-jcc\/jjab213","article-title":"Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA Registry","volume":"16","author":"Calafat","year":"2022","journal-title":"J Crohn\u2019s Colitis."},{"key":"2025120914514399700_izaf172-B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-014-0075-y","article-title":"Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review","author":"Stoner","year":"2014","journal-title":"Patient."},{"key":"2025120914514399700_izaf172-B11","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology."},{"key":"2025120914514399700_izaf172-B12","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025120914514399700_izaf172-B13","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre cohort study","volume":"16","author":"Smith","year":"2022","journal-title":"J Crohn\u2019s Colitis."},{"key":"2025120914514399700_izaf172-B14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.20524\/aog.2023.0816","article-title":"Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience","volume":"36","author":"Jeffrey","year":"2023","journal-title":"Ann Gastroenterol."},{"key":"2025120914514399700_izaf172-B15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/apt.17822","article-title":"Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: the REMSWITCH-LT study","volume":"59","author":"Buisson","year":"2024","journal-title":"Aliment Pharmacol Ther."},{"key":"2025120914514399700_izaf172-B16","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.3390\/biomedicines10092130","article-title":"Subcutaneous infliximab [CT-P13], a true biologic 2.0. Real clinical practice multicentre study","volume":"10","author":"Huguet","year":"2022","journal-title":"Biomedicines."},{"key":"2025120914514399700_izaf172-B17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12919-021-00230-7","article-title":"Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert\u2019s and patient\u2019s perspective","volume":"15","author":"Jonaitis","year":"2021","journal-title":"BMC Proc."},{"key":"2025120914514399700_izaf172-B18","doi-asserted-by":"publisher","first-page":"e14283","DOI":"10.1111\/eci.14283","article-title":"An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: the TIME study","volume":"54","author":"D\u2019Amico","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"2025120914514399700_izaf172-B19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/ibd\/izad094","article-title":"One-year clinical outcomes of subcutaneous infliximab maintenance therapy compared with intravenous infliximab maintenance therapy in patients with inflammatory bowel disease: a prospective cohort study","volume":"30","author":"Hong","year":"2024","journal-title":"Inflamm Bowel Dis."},{"key":"2025120914514399700_izaf172-B20","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology."},{"key":"2025120914514399700_izaf172-B21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/ibd\/izac119","article-title":"Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 study","volume":"29","author":"Buisson","year":"2023","journal-title":"Inflamm Bowel Dis."},{"key":"2025120914514399700_izaf172-B22","doi-asserted-by":"publisher","first-page":"e001105","DOI":"10.1136\/bmjgast-2023-001105","article-title":"Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)","volume":"10","author":"Carbery","year":"2023","journal-title":"BMJ Open Gastroenterol."},{"key":"2025120914514399700_izaf172-B23","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/ecco-jcc\/jjae059","article-title":"Intravenous versus subcutaneous infliximab in inflammatory bowel disease: a systematic review and meta-analysis","volume":"18","author":"Chetwood","year":"2024","journal-title":"J Crohn\u2019s Colitis."},{"key":"2025120914514399700_izaf172-B24","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an Update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/12\/3363\/64218018\/izaf172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/12\/3363\/64218018\/izaf172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T19:51:50Z","timestamp":1765309910000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/12\/3363\/8248829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,7]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,7]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf172","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,7]]}}}